Loading…
INAB
In8bio Inc
NASDAQ· Healthcare· Biotechnology· CUSIP 45674E208
$1.04-0.48%Price as of Aug 29, 18:45 UTC · updated once a day, after the close
Key metrics
- Market cap
- $10.2M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.6x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.30
- ROE
- -111.11%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.28
- 52-week high
- $2.73
- 52-week low
- $0.88
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.5% over 5Y.
today you would have $5.84▼ -99.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $2.34 | $7.71 | $41.40 | $69.30 | $131.70 | |
| P/B | 2.0x | 0.8x | 1.6x | 2.4x | 2.5x | — |
| EPS | -$4.44 | -$17.05 | -$30.00 | -$40.80 | -$44.10 | |
| ROE | -122.90% | -70.54% | -210.23% | -120.33% | -125.47% | — |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BFRGBullFrog AI Holdings, Inc. | $0.54 | — | 1.4x | — | -130.71% | $10.01M |
| SINTSintx Technologies, Inc. | $1.50 | — | 2.1x | — | -255.86% | $10M |
| APREAprea Therapeutics, Inc. | $0.84 | — | 0.3x | — | -46.15% | $10.56M |
| AMSAmerican Shared Hospital Services | $1.47 |
About the company
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
- 18
- New York, United States
Company description provided by Yahoo Finance.